Sorry, Shkreli: Supreme Court rebuffs ex-pharma CEO's final appeal
The U.S. Supreme Court refused to hear former Retrophin CEO Martin Shkreli's appeal to overrun his 2017 fraud conviction. (Getty)
Martin Shkreli, the disgraced former CEO of Retrophin currently serving a seven-year sentence for securities fraud and conspiracy, was hoping for a SCOTUS Hail Mary after multiple appeals fell flat. Turns out the court wasn't interested in hearing Shkreli's pleas at all.
The U.S. Supreme Court on Monday denied hearing Shkreli's appeal to overturn his 2017 fraud conviction after his disastrous run as head of biotech Retrophin. Shkreli was also forced to forfeit $7.36 million in his conviction.
With that final rebuff, Shkreli will likely see the inside of a jail cell for the next five years––a sentence that could grow longer after he was accused of running his business from behind bars.
Sponsored by Lubrizol Life Science
[Webinar] Cannabinoid Formulation - from Farm to Pharma
Wednesday, June 24, 2020 | 12pm ET / 9am PT
A handful of cannabinoid-based pharmaceutical products are on the market today, and an ever-growing number are in the global development pipeline. This webinar will explore key considerations in developing cannabinoid-based pharmaceutical products, including an overview of global pharmaceutical cannabinoid usage today, common challenges formulating with CBD and other cannabinoids, and more.